Heart Failure
Bayer’s grant funds educational projects on HFmrEF/HFpEF, highlighting disease burden, treatment gaps, and the science of non-steroidal MRAs using recent clinical trial data.
Funder: Bayer
Due Dates: Rolling (monthly review of complete proposals)
Funding Amounts: Varies by project; detailed budget required in application.
Summary: Supports educational initiatives on heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), emphasizing disease burden, treatment gaps, and the role of non-steroidal MRAs.
Key Information: Allow at least 45 days for review; proposals must meet commercial support standards (e.g., ACCME).
Description
This grant, offered by Bayer, is designed to support educational activities focused on heart failure, particularly heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF, LVEF ≥40%). The initiative aims to improve knowledge of disease burden, pathophysiology, epidemiology, and the significance of co-morbid conditions. It highlights contemporary definitions of HFmrEF/HFpEF, real-world use of recommended therapies, treatment gaps, and residual risks.
A core emphasis is placed on the unique properties, efficacy, safety, and tolerability of non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone, compared to steroidal MRAs, with reference to recent clinical trial data (notably FINEARTS-HF and FINEHEART). Educational formats may include enduring materials, downloadable slides, social media outreach, podcasts, and live virtual events.
